ReviewEuropean psychiatry : the journal of the Association of European Psychiatrists2022
Exosomes in schizophrenia: Pathophysiological mechanisms, biomarkers, and therapeutic targets.
Review in European psychiatry : the journal of the Association of European Psychiatrists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Interrelationships between Cytokines and Schizophrenia: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- LncRNA-miRNA‒mRNA Network in Schizophrenia.Journal of molecular neuroscience : MN · 2025Article
- The multiomics landscape of plasma exosomes in first-episode drug-naïve of schizophrenia.BMC psychiatry · 2025Article
- CircRNA-miRNA-mRNA networks in plasma extracellular vesicles as biomarkers for first-onset schizophrenia.BMC psychiatry · 2025Article
- The Role of Microglial Exosomes in Clozapine Treatment: Effect on Cognition in Schizophrenia.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Review
- Peripheral Circular RNA Expression Levels in Schizophrenia and Schizoaffective Disorder: Associations with Clinical Characteristics and Behavioral Phenotypes.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2025Article
- The roles of extracellular vesicles in mental disorders: information carriers, biomarkers, therapeutic agents.Frontiers in pharmacology · 2025Review
- Profiling expressing features of surface proteins on single-exosome in first-episode Schizophrenia patients: a preliminary study.Schizophrenia (Heidelberg, Germany) · 2024Article
- Plasma miRNAs as potential biomarkers for schizophrenia in a Jordanian cohort.Non-coding RNA research · 2024Article
- Emergence of Extracellular Vesicles as "Liquid Biopsy" for Neurological Disorders: Boom or Bust.Pharmacological reviews · 2024Review
- Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome.Biomedicines · 2024Article
- Review
- Brain disease research based on functional magnetic resonance imaging data and machine learning: a review.Frontiers in neuroscience · 2023Review
- Editorial: New insights into schizophrenia-related neural and behavioral phenotypes.Frontiers in cellular neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While schizophrenia (SCZ) is a devastating psychiatric disorder that detrimentally affects a significant portion of the worldwide population, its diagnosis is traditionally based on a relatively subjective assessment of current symptoms and medical history, devoid of an objective diagnostic modality. Antipsychotic medications are commonly used in the treatment of SCZ; however, some patients have low remission rates or forsake treatment due to the associated multiple side effects, resulting in recurrent episodes of the disease and poor prognosis. These situations imply that the diagnosis, treatment, and prognosis of SCZ need to be improved to increase the odds of a better outcome. Mounting studies have found that extracellular vesicles (EVs) play essential roles in the central nervous system. They are implicated in several mechanisms closely associated with SCZ such as cellular communication and synaptic plasticity. They can additionally exhibit neuroprotective and therapeutic effects. Since they possess distinct constituents, are readily available, easily detectable, and dependent on the internal environment, they can potentially serve as reliable biomarkers for disease diagnosis. Moreover, their biological configuration along with their ability to increase the bioavailability of their constituents and modulate intricate intracellular reactions in target cells, propel EVs as new targets for treatment. This review paper summarizes relevant research pertaining to the roles of EVs in SCZ, with the aim of improving insights into SCZ pathogenesis and evaluating EVs as potential biomarkers in the diagnosis and treatment of SCZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.